Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100 - Yahoo Finance

Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100  Yahoo Finance

Inovio Pharmaceuticals, Inc. INO announced that it has completed enrollment in a phase II study evaluating its lead HPV immunotherapy — VGX-3100 — for the ...



Comments

Popular posts from this blog

Types of skin cancer and how to spot them - Jersey's Best

What to do about skin tags, moles and other bumps - The Washington Post

STIs With Flu-Like Symptoms